Rivastigmine is a cholinesterase inhibitor used for the treatment of mild to moderate dementia of the Alzheimer's type and dementia associated with Parkinson's disease. It works by increasing the levels of acetylcholine in the brain, which helps improve thinking, memory, and cognitive function.

Donepezil is a centrally acting, reversible acetylcholinesterase inhibitor. It is a primary pharmacological treatment for Alzheimer's disease, indicated for the symptomatic management of mild, moderate, and severe dementia, aiming to improve or stabilise cognitive function and daily activities.